great thoughts as usual. I certainly hope its done by June 30 -...

First 12 Last

Share
Profile

Follow
Van88

1,995 Posts.

109

06/04/18

08:47

Post #: 32260492
Share

Originally posted by Maysgr ↑

Realm have already stated they are restricted from raising capital under the takeover bid AND and also due to ASX rules.

The restrictions started when the bid was announced (lasting 3 months), unless the ASX grant relief (and I can't currently see them doing this).
There are also restrictions in place under the bid that last until the bid fails, lapses or is withdrawn.

There won't be a capital raising by Realm any time soon.

My take on this is as follows

- Taurus has extended the bid, even though it is still 11 days until it's original expiry.
- This has been done, in my opinion, to provide certainty to those other companies currently looking at the books and considering an alternative proposal
- Taurus have not increased the bid
- Taurus know the 90c offer will be unsuccessful
- Taurus have not increased the bid because they want to see what happens with the 3rd parties looking at the books.
- Taurus, in my opinion, will be happy to sell to a 3rd party if they can get a price they are happy with, as opposed to purchasing and running the mine themselves.

My opinion is Taurus want this finalised by June 30, so they can make their books look good for the end of the financial year.

I await the next announcement.

Expand

great thoughts as usual.

I certainly hope its done by June 30 - things are just getting a bit drawn out to the point where its becoming ridiculous.

RRP Price at posting: 8.5¢ Sentiment: Hold Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

SPR

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

SRL

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

PL3

Patagonia looks to raise $2.15M for South American exploration and development

MSB

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

OCC

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally